Compounds > quinuclidines
Page last updated: 2024-08-18

quinuclidines and Melanoma

quinuclidines has been researched along with Melanoma in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Borrego, JF; Huelsmeyer, MK; Kurzman, ID; Miller, SA; Muszynski, JL; Pinkerton, ME; Vail, DM1
Awada, A; Ghanem, G; Journe, F; Krayem, M; Marine, JC; Morandini, R; Najem, A; Salès, F; Sibille, C; van Kempen, LC; Wiedig, M1
Bao, W; Chen, M; Issaeva, N; Kumar, R; Selivanova, G; Spinnler, C; Strömblad, S; Thullberg, M; Zhao, X1
Hafsi, H; Hainaut, P1
Bassett, R; Bedikian, AY; Homsi, J; Hwu, P; Hwu, WJ; Kim, K; Mahoney, S; Noor, R; Papadopoulos, N1

Trials

1 trial(s) available for quinuclidines and Melanoma

ArticleYear
Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2012, Volume: 20, Issue:10

    Topics: Antiemetics; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Interleukin-2; Isoquinolines; Male; Melanoma; Middle Aged; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting

2012

Other Studies

4 other study(ies) available for quinuclidines and Melanoma

ArticleYear
Neurokinin-1 receptor expression and antagonism by the NK-1R antagonist maropitant in canine melanoma cell lines and primary tumour tissues.
    Veterinary and comparative oncology, 2016, Volume: 14, Issue:2

    Topics: Animals; Cell Line, Tumor; Dog Diseases; Dogs; Gene Expression Regulation, Neoplastic; Melanoma; Mice; Mice, Nude; Neoplasms, Experimental; Neurokinin-1 Receptor Antagonists; Quinuclidines; Receptors, Neurokinin-1; RNA, Messenger

2016
p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 55

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Genetic Predisposition to Disease; Humans; Indoles; Male; Melanoma; Mice, Nude; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinase; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Quinuclidines; Signal Transduction; Skin Neoplasms; Sulfonamides; Time Factors; Tumor Suppressor Protein p53; Vemurafenib; Xenograft Model Antitumor Assays

2016
PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo.
    Cell cycle (Georgetown, Tex.), 2011, Jan-15, Volume: 10, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Apoptotic Protease-Activating Factor 1; Caspase 3; Caspase 9; Cell Culture Techniques; Cell Line, Tumor; Humans; Melanoma; Mice; Mice, Nude; Proto-Oncogene Proteins; Quinuclidines; RNA Interference; RNA, Small Interfering; Transplantation, Heterologous; Tumor Suppressor Protein p53

2011
Pharmacological rescue of p53 in cancer cells: the soloist meets the PRIMA donna.
    Cell cycle (Georgetown, Tex.), 2011, Mar-15, Volume: 10, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Humans; Melanoma; Protein Folding; Quinuclidines; Tumor Suppressor Protein p53

2011